Effect of constant administration of a gonadotropin-releasing hormone agonist on reproductive activity in mares: preliminary evidence on suppression of ovulation during the breeding season.
During the breeding season, the effect of constant administration of an agonist analog of gonadotropin-releasing hormone (GnRH; goserelin acetate) on reproductive activity of mares was determined. Twenty-four mares undergoing estrous cycles were allocated at random to 6 groups (n = 4/group) and, on May 29 (day 0), received no treatment (group 1, controls), 120 micrograms (group 2), 360 micrograms (group 3), 600 micrograms (group 4), or 1,200 micrograms (group 5) of GnRH agonist/d for 28 days via a depot implanted subcutaneously. The final group of mares (group 6) was treated with 120 micrograms of GnRH agonist/d for 84 days (3 occasions at 28-day intervals). During a pretreatment period (April 19 to May 29) and for 90 days after initiation of GnRH agonist treatment, follicular development and ovulation were monitored by transrectal ultrasonography of the reproductive tract at 2- to 3-day intervals. On each occasion a blood sample was collected for determination of luteinizing hormone (LH) and progesterone. Estrous behavior was monitored by teasing of mares with a stallion. Initiation of agonist treatment was random, relative to the stage of the estrous cycle, and all mares ovulated within 11 days before or after implantation. In 3 of 4 nontreated control mares, estrous cycles were observed throughout the study, with interovulatory intervals ranging from 18 to 26 days. In the remaining mare, concentration of progesterone was high after asynchronous double ovulation during the pretreatment period, suggestive of persistent corpus luteum.(ABSTRACT TRUNCATED AT 250 WORDS)
Fitzgerald
B P
BP
Department of Veterinary Science, Maxwell Gluck Equine Research Center, University of Kentucky, Lexington 40546-0099.
Peterson
K D
KD
Silvia
P J
PJ
D000818:Animals; D001947:Breeding / Q000379:methods*; D004334:Drug Administration Schedule; D005260:Female; D017273:Goserelin / Q000008:administration & dosage / Q000494:pharmacology*; D006736:Horses / Q000097:blood / Q000502:physiology*; D007986:Luteinizing Hormone / Q000097:blood; D010060:Ovulation / Q000187:drug effects* / Q000502:physiology; D011374:Progesterone / Q000097:blood
D017273:Goserelin; D011374:Progesterone; D007986:Luteinizing Hormone